Atroposelective Synthesis of Biaryl N ‐Oxides via Cu‐Catalyzed De Novo Heteroaromatic N ‐Oxide Ring Formation
Advanced Science · 2024
DOI: 10.1002/advs.202405743 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2024. Verfasst von Ke Ma und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Southwestern Chinese Medicine Resources, Hospital of Chengdu University of Traditional Chinese Medicine, School of Pharmacy, …. Hauptthemen laut MEDLINE: Copper, Oxides. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Science & Technology Department of Sichuan Province, Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine.
Abstract (Originalsprache)
Heteroaromatic N ‐oxides, renowned for their highly polar N─O bond and robust structure, exhibit significant bioactivities and have played a pivotal role in various drug development projects since the discovery of Minoxidil. Moreover, heteroaromatic N ‐oxides, featuring axially chiral biaryl frameworks, are indispensable as Lewis base catalysts and ligands in organic synthesis. Despite their importance, synthesizing these chiral compounds is challenging, necessitating chiral starting materials or resolution processes. Catalytic strategies rely on the functionalization of heteroaromatic N ‐oxide compounds, leading to products with a relatively limited skeletal diversity. This study introduces a Cu‐catalyzed atroposelective method for synthesizing biaryl N ‐oxides via de novo heteroaromatic N ‐oxide ring formation. This mild and efficient approach achieves excellent stereoselectivities (up to 99:1 er), enabling the production of a wide array of N ‐oxides with novel heteroaromatic scaffolds. The axially chiral N ‐oxide product 3f demonstrates high stereoselectivity and recyclability as a Lewis base catalyst. Additionally, product 3e exhibits promising therapeutic efficacy against triple‐negative breast cancer, with IC 50 values of 4.8 and 5.2 µ m in MDA‐MB‐231 and MDA‐MB‐468 cells, respectively. This research not only advances the synthesis of challenging chiral heteroaromatic N ‐oxides but also encourages further exploration of N ‐oxide entities in the discovery of bioactive small molecules.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Southwestern Chinese Medicine Resources, Hospital of Chengdu University of Traditional Chinese Medicine, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, C…
- Anti-Infective Agent Creation Engineering Research Centre of Sichuan Province, Sichuan Industrial Institute of Antibiotics, School of Pharmacy, Chengdu University, Chengdu, 610106, China.
- Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China.
Förderung
- National Natural Science Foundation of China
- Science & Technology Department of Sichuan Province
- Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine
Zitieren
APA
Ma, K., Qi, T., Hu, L., Chen, C., Wang, W., Li, J. L., Peng, C., Zhan, G., & Han, B. (2024). Atroposelective Synthesis of Biaryl N ‐Oxides via Cu‐Catalyzed De Novo Heteroaromatic N ‐Oxide Ring Formation. Advanced Science. https://doi.org/10.1002/advs.202405743
Vancouver
Ma K, Qi T, Hu L, Chen C, Wang W, Li JL, et al. Atroposelective Synthesis of Biaryl N ‐Oxides via Cu‐Catalyzed De Novo Heteroaromatic N ‐Oxide Ring Formation. Advanced Science. 2024. doi:10.1002/advs.202405743
BibTeX
@article{Ma2024,
author = {Ma, Ke and Qi, Ting and Hu, Lei and Chen, Chen and Wang, Wan and Li, Jun-Long and Peng, Cheng and Zhan, Gu and Han, Bo},
title = {Atroposelective Synthesis of Biaryl N ‐Oxides via Cu‐Catalyzed De Novo Heteroaromatic N ‐Oxide Ring Formation},
journal = {Advanced Science},
year = {2024},
doi = {10.1002/advs.202405743}
}
EUVIMED